Puma Biotechnology Inc. (PBYI)

68.50
1.50 2.20
NASDAQ : Health Technology
Prev Close 67.05
Open 66.30
Day Low/High 66.10 / 68.70
52 Wk Low/High 28.35 / 136.90
Volume 101.63K
Avg Volume 881.30K
Exchange NASDAQ
Shares Outstanding 37.53M
Market Cap 2.34B
EPS -8.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Puma Biotechnology And CANbridge Life Sciences Enter Into Exclusive Licensing Agreement To Commercialize NERLYNX® (neratinib) In Greater China

Puma Biotechnology And CANbridge Life Sciences Enter Into Exclusive Licensing Agreement To Commercialize NERLYNX® (neratinib) In Greater China

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, have entered into an...

Puma Biotechnology Announces Publication Of Results From Phase II SUMMIT 'Basket' Trial Evaluating Neratinib In HER2 And HER3 Mutant Cancers

Puma Biotechnology Announces Publication Of Results From Phase II SUMMIT 'Basket' Trial Evaluating Neratinib In HER2 And HER3 Mutant Cancers

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that initial results from the company's ongoing SUMMIT Phase II 'basket' clinical trial of PB272 (neratinib) in patients with tumors harboring...

Puma Biotechnology And Medison Pharma Enter Into Exclusive Licensing Agreement To Commercialize NERLYNX® (neratinib) In Israel

Puma Biotechnology And Medison Pharma Enter Into Exclusive Licensing Agreement To Commercialize NERLYNX® (neratinib) In Israel

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Medison Pharma Ltd, Israel's leading commercial partner for innovative pharmaceuticals, have entered into an exclusive agreement under which Medison...

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, today announced that on January 16, 2018 the Compensation Committee of Puma's Board of Directors approved the grant of an inducement stock option to...

Puma Biotechnology Announces Results Of CHMP Oral Explanation For Neratinib For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology Announces Results Of CHMP Oral Explanation For Neratinib For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has communicated a negative trend vote after meeting with the Company...

Puma Biotechnology Added To NASDAQ Biotechnology Index

Puma Biotechnology Added To NASDAQ Biotechnology Index

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI) as part of the NBI's annual re-ranking of biotechnology and pharmaceutical...

Puma Biotechnology Announces Meeting Of Scientific Advisory Group On Oncology In Europe To Review Neratinib For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology Announces Meeting Of Scientific Advisory Group On Oncology In Europe To Review Neratinib For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the European Medicines Agency (EMA) has requested that the Scientific Advisory Group on Oncology provide an opinion on the clinical...

Under Armour, Tractor Supply, Enbridge: 'Mad Money' Lightning Round

Under Armour, Tractor Supply, Enbridge: 'Mad Money' Lightning Round

Jim Cramer spotlights Under Armour, Tractor Supply, Enbridge, Casey's General Stores and Puma Biotechnology.

No Two Stocks Are the Same: Cramer's 'Mad Money' Recap (Tuesday 12/12/17)

No Two Stocks Are the Same: Cramer's 'Mad Money' Recap (Tuesday 12/12/17)

In markets like this, Jim Cramer says, tune out the noise and look at individual stocks like Disney, Boeing and Caterpillar.

Daiichi Sankyo And Puma Biotechnology Announce Research Collaboration With Major Cancer Center In HER2-Mutated Cancer

Daiichi Sankyo And Puma Biotechnology Announce Research Collaboration With Major Cancer Center In HER2-Mutated Cancer

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Puma Biotechnology, Inc.

Puma Biotechnology Announces Positive Outcome Of European Opposition Proceedings

Puma Biotechnology Announces Positive Outcome Of European Opposition Proceedings

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the European Patent Office has upheld the claims in Puma's licensed European patent (EP 2416774), which were being opposed by Hexal AG.

CONTROL Trial At SABCS

CONTROL Trial At SABCS

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, will present updated interim results from a Phase II clinical trial of Puma's drug neratinib at the 2017 San Antonio Breast Cancer Symposium (SABCS) that...

Puma Biotechnology And Specialised Therapeutics Asia Enter Into Exclusive Licensing Agreement To Commercialize NERLYNX® (neratinib) In Australia, New Zealand And South East Asia

Puma Biotechnology And Specialised Therapeutics Asia Enter Into Exclusive Licensing Agreement To Commercialize NERLYNX® (neratinib) In Australia, New Zealand And South East Asia

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Specialised Therapeutics Asia, an international biopharmaceutical company with strategic focus and expertise in Australia, New Zealand and South East...

Puma Biotechnology's 5-Year Analysis Of Phase III ExteNET Study Published Online In The Lancet Oncology

Puma Biotechnology's 5-Year Analysis Of Phase III ExteNET Study Published Online In The Lancet Oncology

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the publication of previously presented results from the ExteNET Phase III clinical trial of Puma's drug neratinib in patients with early stage...

Puma Biotechnology Reports Third Quarter 2017 Financial Results

Puma Biotechnology Reports Third Quarter 2017 Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter and nine months ended September 30, 2017.

Puma Biotechnology To Present At Stifel Healthcare Conference

Puma Biotechnology To Present At Stifel Healthcare Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology Secures $100 Million Term Loan From Silicon Valley Bank And Oxford Finance

Puma Biotechnology Secures $100 Million Term Loan From Silicon Valley Bank And Oxford Finance

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, has entered into a loan agreement with Silicon Valley Bank, the bank of the world's most innovative companies and their investors, and Oxford Finance, a...

Puma Biotechnology To Present At Credit Suisse Healthcare Conference

Puma Biotechnology To Present At Credit Suisse Healthcare Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology To Host Conference Call To Discuss Third Quarter Financial Results

Puma Biotechnology To Host Conference Call To Discuss Third Quarter Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.

Short Interest In Puma Biotechnology Falls 51.2%

Short Interest In Puma Biotechnology Falls 51.2%

The most recent short interest data has been released for the 09/29/2017 settlement date, which shows a 3,509,935 share decrease in total short interest for Puma Biotechnology Inc , to 3,338,965, a decrease of 51.25% since 09/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Noteworthy Wednesday Option Activity: PBYI, MBI, XON

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Puma Biotechnology Inc , where a total volume of 6,609 contracts has been traded thus far today, a contract volume which is representative of approximately 660,900 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 89.5% of PBYI's average daily trading volume over the past month, of 738,030 shares.

Puma Biotechnology To Present At Cantor Fitzgerald Healthcare Conference

Puma Biotechnology To Present At Cantor Fitzgerald Healthcare Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology Presents 5-Year Analysis Of Phase III ExteNET Trial In Extended Adjuvant HER2-Positive Breast Cancer At ESMO 2017 Congress

Puma Biotechnology Presents 5-Year Analysis Of Phase III ExteNET Trial In Extended Adjuvant HER2-Positive Breast Cancer At ESMO 2017 Congress

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the presentation of positive results from the Phase III clinical trial of Puma's drug neratinib for the extended adjuvant treatment of early...

Puma Biotechnology To Participate In Panel Discussion At Citi's Biotech Conference

Puma Biotechnology To Participate In Panel Discussion At Citi's Biotech Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology Announces Publication Of Abstracts For ESMO 2017

Puma Biotechnology Announces Publication Of Abstracts For ESMO 2017

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the release of two abstracts on its drug neratinib that will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress,...

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, today announced that on August 15, 2017 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit...